Edesa Biotech, Inc. Stock News

Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility & Risk Edesa Biotech has a beta of 0.59, suggesting that its share price [] The post Edesa Biotech (NASDAQ:EDSA) and Dyne Therapeutics (NASDAQ:DYN) Financial Survey appeared first on ETF Daily News .

Equities analysts forecast that Edesa Biotech, Inc. (NASDAQ:EDSA) will report earnings per share (EPS) of ($0.35) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Edesa Biotechs earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.42). Edesa Biotech posted earnings of ($0.22) per share during the same []

Vanguard Group Inc. raised its stake in Edesa Biotech, Inc. (NASDAQ:EDSA) by 88.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 109,158 shares of the companys stock after buying an additional 51,369 shares during the quarter. Vanguard Group Inc. owned approximately 0.82% of Edesa Biotech worth $576,000 []

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related: �

Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19.  Edesa reported th

Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for

On Sep 20, EDSA reports positive p2 data. On a request of the DSMB (Data and Safety Monitoring Board), p2 portion of EDSA's ongoing p2/3 trial was "preemptively unblinded".

Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. The post EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Mo

Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients dem

Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a

The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 60% pre-market. This is why it happened.

Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Dat

Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients. Edesa report

Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORO

TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial